Latest research on Levetiracetam

Levetiracetam is an anticonvulsant medication used to treat epilepsy. Levetiracetam may selectively prevent hypersynchronization of epileptiform burst firing and propagation of seizure activity. Levetiracetam binds to the synaptic vesicle protein SV2A, which is thought to be involved in the regulation of vesicle exocytosis. Although the molecular significance of levetiracetam binding to synaptic vesicle protein SV2A is not understood, levetiracetam and related analogs showed a rank order of affinity for SV2A which correlated with the potency of their antiseizure activity in audiogenic seizure-prone mice.

Latest findings

Thereby, the most investigated anti-epileptic treatment was Levetiracetam with 17 published trials and six unpublished trials. [source, 2016]
Given that mainly Levetiracetam is thought to have an effect on PAS measures (see Discussion), analyses were repeated in a subgroup of patients without Levetiracetam medication and with mRS > 0 (n = 19). [source, 2016]
Previous studies showed an effect mainly for Levetiracetam on the PAS protocol, whereas most drugs did not affect this measurement, such as tiagabine, Diazepam, Lamotrigine, piracetam, Gabapentin, and Topiramate. [source, 2016]
Reanalysis of our data using both a subgroup of patients lacking Levetiracetam and patients lacking all CNS‐active medications lead to equal results confirming the significant PAS differences between NMDAR encephalitis patients and controls. [source, 2016]
When comparing all encephalitis patients with controls, we found significant differences in RMT which was not detectable in the subgroup without centrally active medication (including all drugs such as tiagabine, Diazepam, Lamotrigine, piracetam, Gabapentin, Topiramate, and Levetiracetam). [source, 2016]
Even though there is somewhat conflicting data whether Levetiracetam has large or subtle effects on single‐pulse TMS parameters,37, 38, 39 we conclude that the observed differences in RMT might partially depend on medication, while the observed PAS effect is most likely related to receptor changes attributable to NMDAR encephalitis. [source, 2016]
The anticonvulsants preferred for the treatment of acute symptomatic seizures are those available for intravenous use, such as benzodiazepines, Fosphenytoin or phenytoin, Valproate, Levetiracetam, and Phenobarbital [6]. [source, 2016]
The cortical tubers were the likely etiology of her seizure and the patient was placed on Keppra but more concerning was the astrocytoma mass in the body of the right lateral ventricle. [source, 2016]
Her seizures have since been well controlled, with low dose treatment with Levetiracetam. [source, 2016]
She was started on Levetiracetam. [source, 2016]